Table 5.
Reported vaccine-related adverse events by the groups among participants.
| Adverse events | SARS-CoV-2 + IIV4/PPV23 group N=203 | SARS-CoV-2 + PPV23/IIV4 group N=206 | SARS-CoV-2/IIV4+PPV23 group N=203 | P value |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| TOTAL | 30(14.78) | 28(13.59) | 32(15.76) | 0.834 |
| Solicited adverse reactions | 29(14.29) | 27(13.11) | 29(14.29) | 0.925 |
| Systematic | 8(3.94) | 7(3.40) | 11(5.42) | 0.594 |
| Fever | 3(1.48) | 2(0.97) | 1(0.49) | 0.707 |
| Cough | 1(0.49) | 2(0.97) | 3(1.48) | 0.707 |
| Headache | 2(0.99) | 0(0.00) | 5(2.46) | 0.038 |
| Nausea | 2(0.99) | 0(0.00) | 1(0.49) | 0.329 |
| Fatigue | 4(1.97) | 5(2.43) | 5(2.46) | 1.000 |
| Myalgia | 2(0.99) | 2(0.97) | 7(3.45) | 0.116 |
| Diarrhea | 0(0.00) | 1(0.49) | 2(0.99) | 0.551 |
| Myalgia | 0(0.00) | 0(0.00) | 2(0.99) | 0.219 |
| Local | 24(11.82) | 24(11.65) | 26(12.81) | 0.951 |
| Pain | 24(11.82) | 21(10.19) | 24(11.82) | 0.829 |
| Rash | 0(0.00) | 1(0.49) | 0(0.00) | 1.000 |
| Pain | 0(0.00) | 3(1.46) | 1(0.49) | 0.331 |
| Induration | 2(0.99) | 9(4.37) | 6(2.96) | 0.111 |
| Unsolicited adverse reactions | 9(4.43) | 5(2.43) | 10(4.93) | 0.360 |
| Systematic | 0(0.00) | 0(0.00) | 1(0.49) | 0.663 |
| Fatigue | 0(0.00) | 0(0.00) | 1(0.49) | 0.663 |
| Myalgia | 0(0.00) | 0(0.00) | 1(0.49) | 0.663 |
| Local | 0(0.00) | 1(0.49) | 0(0.00) | 1.000 |
| Pain | 0(0.00) | 1(0.49) | 0(0.00) | 1.000 |
| Others | 9(4.43) | 4(1.94) | 9(4.43) | 0.305 |